Status:
UNKNOWN
DCB Treatment in CTO Guided by IVUS
Lead Sponsor:
Xuzhou Central Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
The percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) coronary artery disease is difficult, the success rate is low, and the incidence of re-occlusion and restenosis is high. ...
Eligibility Criteria
Inclusion
- Over the age of 18, male or female;
- Patients who meet the diagnostic criteria for coronary heart disease, have clinical symptoms and seek interventional treatment;
- Coronary angiography confirmed that the blood vessels met the diagnostic criteria of CTO;
- Sign informed consent and be willing to undergo follow-up for at least 12 months.
Exclusion
- Patients with severe contrast allergy who cannot tolerate coronary angiography;
- Patients known allergy to drug balloon coating;
- Patients who is pregnant or breastfeeding;
- Bleeding or other diseases, such as digestive tract ulcers, blood system diseases, etc., limit the use of platelet aggregation inhibitors and anticoagulation therapy;
- Patients with cardiac shock;
- Patients with a life expectancy of less than 1 year;
- Other situations deemed unsuitable for inclusion by the researcher.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06050096
Start Date
September 1 2023
End Date
October 1 2025
Last Update
September 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuzhou Central Hospital
Xuzhou, Jiangsu, China, 221000